全文获取类型
收费全文 | 42412篇 |
免费 | 5809篇 |
国内免费 | 1431篇 |
专业分类
耳鼻咽喉 | 185篇 |
儿科学 | 1123篇 |
妇产科学 | 401篇 |
基础医学 | 5708篇 |
口腔科学 | 758篇 |
临床医学 | 4638篇 |
内科学 | 7211篇 |
皮肤病学 | 1060篇 |
神经病学 | 2471篇 |
特种医学 | 713篇 |
外国民族医学 | 8篇 |
外科学 | 2997篇 |
综合类 | 5109篇 |
现状与发展 | 12篇 |
一般理论 | 1篇 |
预防医学 | 3590篇 |
眼科学 | 898篇 |
药学 | 7794篇 |
76篇 | |
中国医学 | 2054篇 |
肿瘤学 | 2845篇 |
出版年
2024年 | 72篇 |
2023年 | 1302篇 |
2022年 | 1409篇 |
2021年 | 2683篇 |
2020年 | 2698篇 |
2019年 | 2384篇 |
2018年 | 2115篇 |
2017年 | 2252篇 |
2016年 | 2117篇 |
2015年 | 1987篇 |
2014年 | 3001篇 |
2013年 | 3441篇 |
2012年 | 2548篇 |
2011年 | 2652篇 |
2010年 | 2204篇 |
2009年 | 1795篇 |
2008年 | 1768篇 |
2007年 | 1686篇 |
2006年 | 1521篇 |
2005年 | 1264篇 |
2004年 | 1104篇 |
2003年 | 1070篇 |
2002年 | 853篇 |
2001年 | 816篇 |
2000年 | 586篇 |
1999年 | 519篇 |
1998年 | 403篇 |
1997年 | 334篇 |
1996年 | 299篇 |
1995年 | 287篇 |
1994年 | 256篇 |
1993年 | 220篇 |
1992年 | 221篇 |
1991年 | 254篇 |
1990年 | 177篇 |
1989年 | 139篇 |
1988年 | 148篇 |
1987年 | 172篇 |
1986年 | 140篇 |
1985年 | 144篇 |
1984年 | 138篇 |
1983年 | 85篇 |
1982年 | 115篇 |
1981年 | 71篇 |
1980年 | 55篇 |
1979年 | 38篇 |
1978年 | 21篇 |
1977年 | 31篇 |
1976年 | 22篇 |
1973年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
101.
《Vaccine》2022,40(12):1872-1878
BackgroundThe MenB-FHbp vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age. The clinical development program included 11 completed trials where, in each trial, MenB-FHbp had an acceptable safety profile after a primary vaccination series was administered to individuals 10–65 years of age. However, the detection of potential rare events was limited because of individual clinical trial size. The current safety analysis evaluates pooled reactogenicity and other adverse events (AEs) reported in these trials to identify new safety signals not detectable in individual trials.MethodsEleven trials contributed safety data, of which 10 recorded local and systemic reactogenicity events; 8 of the trials were controlled, and reactogenicity data were pooled for 7 of these 8 trials. Additional AE evaluations included immediate AEs (IAEs), medically attended AEs (MAEs), serious AEs (SAEs), newly diagnosed chronic medical conditions (NDCMCs), and autoimmune or neuroinflammatory conditions.ResultsLocal and systemic reactions were more frequent in the MenB-FHbp group (n = 15,294) compared with controls (n = 5509), although most reactions were transient and mild to moderate in severity. Frequencies of IAEs, SAEs, MAEs, NDCMCs, and autoimmune or neuroinflammatory conditions were similar between the MenB-FHbp and control groups.ConclusionsMenB-FHbp demonstrated a favorable safety and tolerability profile in the clinical development program of > 15,000 vaccine recipients ≥ 10 years of age. No new safety signals were identified in the pooled analysis compared with data from the individual trials. Continued postmarketing safety surveillance is important for the identification of rare events.Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117. 相似文献
102.
Kari Hemminki MD PhD Kristina Sundquist MD PhD Jan Sundquist MD PhD Asta Försti PhD Vaclav Liska MD PhD Akseli Hemminki MD PhD Xinjun Li MD PhD 《Cancer》2023,129(8):1227-1236
Background
Autoimmune diseases are associated with many cancers but there is a lack of population-based studies with different autoimmune diseases that have a long follow-up. This is also true of hepatobiliary cancers, which include hepatocellular cancer (HCC) and rarer entities of gallbladder cancer (GBC), intra- and extrahepatic cholangiocarcinoma (iCCA and eCCA), and ampullary cancer.Methods
Diagnostic data on 43 autoimmune diseases were collected from the Swedish Inpatient Register from 1987 to 2018, and cancer data were derived from the national cancer registry from 1997 onward. Relative risks were expressed as standardized incidence ratios (SIRs).Results
In a population of 13.6 million, 1.1 million autoimmune diseases were diagnosed and subsequent hepatobiliary cancer was diagnosed in 3191 patients (17.2% of cancers). SIRs for HCC were 2.73 (men) and 2.86 (women), 3.74/1.96 for iCCA, 2.65/1.37 for GBC, 2.38/1.64 for eCCA, and 1.80/1.85 for ampullary cancer. Significant associations between autoimmune disease and HCC were observed for 13 autoimmune diseases, with the highest risks being for autoimmune hepatitis (48.92/73.53, men/women) and primary biliary cirrhosis (38.03/54.48). GBC was increased after six autoimmune diseases, with high SIRs for ulcerative colitis (12.22/3.24) and men with Crohn disease (9.16). These autoimmune diseases were also associated with a high risk of iCCA, which had seven other associations, and eCCA, which had five other associations. Ampullary cancer occurrence was increased after four autoimmune diseases.Conclusion
An autoimmune disease is a common precursor condition for hepatobiliary cancers. This calls for careful control of autoimmune disease symptoms in each patient and encouragement to practice a healthy lifestyle. 相似文献103.
104.
105.
Rong Ouyang Zhongzhuan Li Peng Peng Jinxiu Zhang Jun Liu Mengbin Qin Jiean Huang 《International journal of medical sciences》2021,18(3):685
Background: Tumor mutation burden (TMB) was correlated with the immunotherapeutic response in various malignancies. We aimed to evaluate the TMB immune signature in colon adenocarcinoma (COAD).Methods: Gene expression profile, mutation and clinical data of COAD patients were obtained from The Cancer Genome Atlas (TCGA) database. The samples were divided into high and low TMB level groups to identify differentially expressed genes (DEGs). Functional enrichments analyzes were performed to identify the biological functions of the DEGs. Then, immune cell infiltration signatures were calculated by the CIBERSORT algorithm. Finally, Cox proportional hazard model was constructed to estimate the prognostic value of the identified immune-related genes.Results: Gene set enrichment analysis in the high-TMB level group showed that DEGS were enriched in immune-related pathways, such as antigen processing and presentation, Toll-like receptor signaling and natural killer cell-mediated cytotoxicity. A higher infiltration level of CD8+ T cells, CD4+ T cells, activated NK cells , M1 Macrophages and T follicular helper cells was observed in the high-TMB level group. Furthermore, a Cox regression model combined with survival analysis based on the expression level of four identified prognostic genes was constructed, validated anf revealed that higher risk-score levels conferred poor survival outcomes in COAD patients.Conclusions: Our data demonstrate that the high TMB levels are associated with an immune signature in COAD and deepen the molecular understanding of TMB function in tumor immunotherapy. 相似文献
106.
《Cancer cell》2021,39(10):1404-1421.e11
107.
108.
【目的】探讨专人专职管理卡介苗( Bacille Calmette-Guerin vaccine,BCG)预防接种的实施效果。【方法】选取2014~2017年在上海市国际和平妇幼保健院出生的新生儿为研究组,2010~2013年出生的新生儿为对照组。通过疑似预防接种异常反应信息管理系统,收集2010~2017年报告的卡介苗预防接种异常反应( adverse events following immunization,AEFI)个案数据,比较专人专职管理前后两组新生儿在卡介苗使用情况及发生BCG AEFI之间的差异。【结果】研究组BCG的AEFI报告发生率、拒种率均低于对照组,差异有统计学意义(p<0.05)。BCG的AEFI分类中直径>1.0cm淋巴结炎最常见,研究组报告发生率为31.31/100万剂,低于对照组205.35/100万剂,差异有统计学意义(p<0.05)。【结论】通过专人专职管理可规范卡介苗的接种,降低AEFI的发生率和拒种率,利于临床推广。 相似文献
109.
Amedeo Lonardo Alessandro Mantovani 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(8):2354-2357
Liver health is a key determinant of cardiovascular risk (CVR). Hepatic fibrosis is the shared common result of chronic hepatitis, irrespective of aetiology. Fibrosis profoundly distorts liver tissue architecture and perturbs hepatic physiology, dictates the course of chronic liver disease and is increasingly recognized as a CVR factor. The relative weights of pre-diabetes and hepatic fibrosis as risk factors for major adverse cardiac events (MACE) in patients with HCV remain an open issue. Sasso and Colleagues answered this research question by treating approximately half of 770 HCV positive pre-diabetic patients with direct antiviral agents (DAAs), while the rest served as historical controls. Data have shown that achieving HCV clearance with DAAs was associated with a 60% reduced risk of MACE, thereby implying that this antiviral strategy is recommended in HCV positive pre-diabetic patients, regardless of the severity of liver disease and concurrent CVR factors. This study paves the way for additional studies addressing the molecular patho-mechanisms and changes in the clinical spectrum involved in cardio-metabolic protection following HCV eradication in patients with pre-diabetes. 相似文献
110.